Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis
Introduction: Hepatitis A virus (HAV) is a causative agent of acute hepatitis in humans, infecting more than one million individuals every year, including both symptomatic and asymptomatic infections. The currently available preventive vaccines for HAV are based on either wild-type or live-attenu...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pasteur Institute of Iran
2023-09-01
|
| Series: | Journal of Medical Microbiology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://jommid.pasteur.ac.ir/article-1-568-en.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849312999497531392 |
|---|---|
| author | Mina Hannan1 Leila Jabalameli1* Mohammad Reza Aghasadeghi2* Naser Harzandi1 Seyed Mehdi Sadat2 |
| author_facet | Mina Hannan1 Leila Jabalameli1* Mohammad Reza Aghasadeghi2* Naser Harzandi1 Seyed Mehdi Sadat2 |
| author_sort | Mina Hannan1 |
| collection | DOAJ |
| description | Introduction: Hepatitis A virus (HAV) is a causative agent of acute hepatitis
in humans, infecting more than one million individuals every year, including
both symptomatic and asymptomatic infections. The currently available
preventive vaccines for HAV are based on either wild-type or live-attenuated
virus strains, which can contribute to the costliness of the vaccination
process. Therefore, it may be worthwhile to explore the potential of subunit
vaccines that utilize immunogenic viral products. Methods: This study
presents the results of a novel recombinant protein production study that
employed the native structures of HAV-VP1 and HBs-Ag. The fusion
protein underwent comprehensive characterization to evaluate its potential
applications in diagnostics and immunization. The truncated recombinant
protein, HAV-VP1 (position 99-259 aa) -HBs-Ag, was successfully
expressed in the Escherichia coli BL21-DE3 system. Results: The
recombinant protein, with a molecular weight of 46 kDa, was evaluated
using SDS-PAGE gel electrophoresis and confirmed by western blotting.
The fusion protein was successfully detected in serum samples positive for
HBV or HAV using anti-HBs and anti-VP1 antibodies. Additionally, it
elicited a potent humoral response in BALB/c mice. Conclusion: The novel
recombinant protein described in this study has the potential to serve as a
bivalent vaccine against HAV and HBV infections. The next step involves
evaluating the immunogenicity and safety profile of the protein. |
| format | Article |
| id | doaj-art-eefa3f871eb04d26b56d8ea1c95ab45d |
| institution | Kabale University |
| issn | 2345-5349 2345-5330 |
| language | English |
| publishDate | 2023-09-01 |
| publisher | Pasteur Institute of Iran |
| record_format | Article |
| series | Journal of Medical Microbiology and Infectious Diseases |
| spelling | doaj-art-eefa3f871eb04d26b56d8ea1c95ab45d2025-08-20T03:52:55ZengPasteur Institute of IranJournal of Medical Microbiology and Infectious Diseases2345-53492345-53302023-09-0111312813510.61186/JoMMID.11.3.128Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and DiagnosisMina Hannan10https://orcid.org/0000-0001-5721-1376Leila Jabalameli1*1https://orcid.org/0000-0003-4208-4401Mohammad Reza Aghasadeghi2*2https://orcid.org/0000-0003-2186-0774Naser Harzandi13https://orcid.org/0000-0003-2783-4462Seyed Mehdi Sadat24https://orcid.org/0000-0001-7739-179X1Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran1Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran2Department of Hepatitis and AIDS and Blood Borne Diseases, Pasteur Institute of Iran, Tehran, Iran1Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran2Department of Hepatitis and AIDS and Blood Borne Diseases, Pasteur Institute of Iran, Tehran, IranIntroduction: Hepatitis A virus (HAV) is a causative agent of acute hepatitis in humans, infecting more than one million individuals every year, including both symptomatic and asymptomatic infections. The currently available preventive vaccines for HAV are based on either wild-type or live-attenuated virus strains, which can contribute to the costliness of the vaccination process. Therefore, it may be worthwhile to explore the potential of subunit vaccines that utilize immunogenic viral products. Methods: This study presents the results of a novel recombinant protein production study that employed the native structures of HAV-VP1 and HBs-Ag. The fusion protein underwent comprehensive characterization to evaluate its potential applications in diagnostics and immunization. The truncated recombinant protein, HAV-VP1 (position 99-259 aa) -HBs-Ag, was successfully expressed in the Escherichia coli BL21-DE3 system. Results: The recombinant protein, with a molecular weight of 46 kDa, was evaluated using SDS-PAGE gel electrophoresis and confirmed by western blotting. The fusion protein was successfully detected in serum samples positive for HBV or HAV using anti-HBs and anti-VP1 antibodies. Additionally, it elicited a potent humoral response in BALB/c mice. Conclusion: The novel recombinant protein described in this study has the potential to serve as a bivalent vaccine against HAV and HBV infections. The next step involves evaluating the immunogenicity and safety profile of the protein.https://jommid.pasteur.ac.ir/article-1-568-en.htmlhepatitis ahepatitis brecombinant proteinpurificationimmunizationdiagnosis |
| spellingShingle | Mina Hannan1 Leila Jabalameli1* Mohammad Reza Aghasadeghi2* Naser Harzandi1 Seyed Mehdi Sadat2 Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis Journal of Medical Microbiology and Infectious Diseases hepatitis a hepatitis b recombinant protein purification immunization diagnosis |
| title | Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis |
| title_full | Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis |
| title_fullStr | Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis |
| title_full_unstemmed | Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis |
| title_short | Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis |
| title_sort | expression and evaluation of a novel hav vp1 and hbs ag fusion protein for potential applications in immunization and diagnosis |
| topic | hepatitis a hepatitis b recombinant protein purification immunization diagnosis |
| url | https://jommid.pasteur.ac.ir/article-1-568-en.html |
| work_keys_str_mv | AT minahannan1 expressionandevaluationofanovelhavvp1andhbsagfusionproteinforpotentialapplicationsinimmunizationanddiagnosis AT leilajabalameli1 expressionandevaluationofanovelhavvp1andhbsagfusionproteinforpotentialapplicationsinimmunizationanddiagnosis AT mohammadrezaaghasadeghi2 expressionandevaluationofanovelhavvp1andhbsagfusionproteinforpotentialapplicationsinimmunizationanddiagnosis AT naserharzandi1 expressionandevaluationofanovelhavvp1andhbsagfusionproteinforpotentialapplicationsinimmunizationanddiagnosis AT seyedmehdisadat2 expressionandevaluationofanovelhavvp1andhbsagfusionproteinforpotentialapplicationsinimmunizationanddiagnosis |